Source link : https://www.newshealth.biz/health-news/rituximab-and-abatacept-may-contribute-to-cancer-risk-in-ra/
TOPLINE: The initiation of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), particularly rituximab and abatacept, is associated with an increased risk for incident cancer in patients with rheumatoid arthritis (RA) within 2 years of starting treatment. METHODOLOGY: The researchers conducted a retrospective cohort study to assess the safety of tumor necrosis factor (TNF) inhibitors, […]
Author : News Health
Publish date : 2024-12-13 12:07:40
Copyright for syndicated content belongs to the linked Source.
inHealth